OSUR logo

OraSure Technologies Stock Price

Symbol: NasdaqGS:OSURMarket Cap: US$238.6mCategory: Healthcare

OSUR Share Price Performance

OSUR Community Fair Values

Recent OSUR News & Updates

No updates

OraSure Technologies, Inc. Key Details

US$161.6m

Revenue

US$92.9m

Cost of Revenue

US$68.8m

Gross Profit

US$100.7m

Other Expenses

-US$32.0m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 05, 2025
Earnings per share (EPS)
-0.43
Gross Margin
42.54%
Net Profit Margin
-19.77%
Debt/Equity Ratio
0%

OraSure Technologies, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About OSUR

Founded
2000
Employees
501
CEO
Carrie Eglinton Manner
WebsiteView website
www.orasure.com

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company’s products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.

U.S. Market Performance

  • 7 Days: -0.6%
  • 3 Months: 11.8%
  • 1 Year: 16.8%
  • Year to Date: 7.5%
In the last week, the market has been flat, with a notable exception in the Healthcare sector dropping 4.2%. More promisingly, the market is up 17% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading